Between allergies and skin rash: the many manifestations of the skin

Initial note: This article was previously published and updated according to scientific and informative criteria to offer the reader a current and verifiable overview of the skin manifestations of allergies. The content is for informational purposes only and does not replace medical advice: for diagnoses or therapies, consult a healthcare professional.

IN BRIEF

• Skin reactions (erythema, itching, blisters, angioedema, etc.) are frequent manifestations associated with different types of hypersensitivity and problems with the skin barrier.
• The skin is a key organ: its integrity, the local immune system, and the skin microbiota modulate the probability and severity of reactions.
• Similar signs (e.g., erythema, itching) can have different causes; differential diagnosis and specific tests (prick test, patch test) are fundamental tools.
• Practical measures (avoiding known exposure, barrier care, high-tolerance products) can limit discomfort, but evidence on preventive interventions is still evolving.

MAIN SECTION
Abstract: what does science say?

Skin reactions associated with allergies constitute a heterogeneous group of conditions in which the skin responds excessively to external substances or stimuli. Various lines of research indicate that the onset and severity of manifestations depend on three main factors: epidermal barrier integrity, type of local immune response (e.g., activity of T lymphocytes and mast cells), and composition of the skin microbiota. Genetic and population studies have shown how barrier defects (e.g., FLG gene mutations) increase the risk of eczema and allergic sensitization. At the same time, the literature shows that the skin microbiota modulates inflammation and bacterial colonization associated with flare-ups. International clinical guidelines for conditions such as urticaria provide diagnostic and therapeutic indications based on consensus. Finally, broad preventive interventions (for example, the early use of emollients in newborns) have produced conflicting results across studies: some small trials and meta-analyses suggest potential benefits, but large-scale evidence does not confirm a clear and consistent effect. The overall interpretation therefore requires an epidemiological and cautious approach: many associations are consolidated, while direct causality and preventive efficacy remain subjects of active research.

How skin allergies manifest

Skin reactions related to hypersensitivity can present with different symptoms: redness, itching, vesicles, dry plaques, itchy wheals (urticaria), or deeper swelling (angioedema). The onset can be immediate (minutes-hours) as in IgE-mediated reactions or delayed (hours-days) as in cell-mediated contact dermatitis. The distribution and appearance of the lesions help the doctor guide the diagnosis: localized lesions are frequent in contact dermatitis, while diffuse forms may reflect systemic exposure or broader immune mechanisms. It is important to emphasize that the same clinical presentation (e.g., redness and itching) is common to many conditions and is not in itself specific to "allergy": infections, chemical irritations, chronic inflammatory diseases, and systemic pathologies can mimic an allergic picture. For this reason, clinical evaluation integrated with personal history and the eventual use of tests (prick test, patch test, immunological examinations) is fundamental to distinguish observational associations from causal relationships.

Biological mechanisms: skin barrier, immune system, and microbiota

The skin is a physical and immunological barrier. The stratum corneum controls water loss and limits the entry of foreign substances: structural or functional defects favor the penetration of antigens and subsequent sensitization. Various genetic studies and meta-analyses have linked FLG gene (filaggrin) mutations to an increased risk of eczema and allergic sensitization, suggesting that loss of barrier integrity is an important predisposing factor [1].

From an immunological point of view, the skin hosts specialized cells (dendritic cells, resident T lymphocytes, mast cells) that coordinate the response. In immediate mechanisms, IgE and mast cells participate in degranulation with the release of histamine, responsible for itching and wheals; in delayed mechanisms, mediating T lymphocytes play a central role, as occurs in contact dermatitis [2][7].

The skin microbiota — the microbial community residing on the skin — influences immunity and the barrier: alterations in diversity or the predominance of opportunistic species (for example, Staphylococcus aureus in some forms of eczema) can aggravate inflammation and hinder healing [3]. Recent research emphasizes that these three elements (barrier, immunity, microbiota) interact contextually and determine the observed clinical phenotype [8].

Common clinical forms: urticaria, angioedema, contact dermatitis, and atopic dermatitis

Urticaria and angioedema: urticaria manifests with rapidly appearing itchy wheals that typically last less than 24 hours each; angioedema affects deeper layers of the skin or mucous membranes and can cause localized swelling and pain. These conditions are often mediated by mast cells and the release of vasoactive mediators; international guidelines collect diagnostic criteria and clinical evaluation pathways for suspected chronic or acute urticaria [5].

Contact dermatitis: can be irritant (non-immunological) or allergic (mediated by a cell-mediated response). The diagnosis of allergic contact dermatitis is based on anamnesis and the patch test, which identifies the responsible allergen; many common allergens include metals (e.g., nickel), resins, perfumes, and preservatives [6].

Atopic dermatitis (atopic eczema): a chronic condition characterized by very dry skin, persistent itching, and flare-ups. It is closely related to skin barrier defects and type 2 immune responses; it often begins in childhood and can precede the development of other atopic diseases (the so-called "atopic march") [1][8].

PRACTICAL SECTION
What it means in practice

For the public: recognizing and describing symptoms (when they appeared, what worsens or improves them, recent exposures) is the first step. Practical measures with consolidated evidence include the use of gentle cleansers, regular skin barrier care (emollients to reduce dryness and microlesions), and limiting known allergen exposure when identified. For acute urticaria, controlling itching symptoms and monitoring for the eventual onset of systemic signs are priorities; in the presence of respiratory symptoms or airway compromise, urgent medical intervention is necessary. The choice of skin products (cosmetics, creams) should prioritize formulations with high tolerability for sensitive skin: simple ingredients, without perfumes or known risky preservatives, and tested on sensitive skin can reduce the risk of local reactions.

It is important not to confuse practical suggestions with personalized therapeutic indications: medical management (drugs, systemic therapies) and diagnostic decisions (allergy or biopsy tests) are the responsibility of dermatologists and allergists.

Diagnosis: which tests and when to request them

Diagnosis begins with a clinical visit and anamnesis. For suspected IgE-mediated allergies, skin prick tests and specific IgE assays are used; for suspected contact dermatitis, the patch test is the gold standard. In cases with diffuse manifestations or suspected systemic reaction, hematological examinations or the involvement of multiple specialists may be necessary. Differential diagnosis is essential: many non-allergic conditions can mimic an allergic reaction. A correct diagnostic sequence helps avoid unnecessary dietary or behavioral restrictions and identify targeted exposure control measures.

Role of diet and common myths

The association between diet and skin manifestations exists, especially when there is a true IgE-mediated food allergy (which can manifest as urticaria or angioedema). However, the idea that diet is the main cause of many chronic dermatoses does not find consistent support: the available evidence is heterogeneous, and in many situations, dietary restriction does not provide clear benefits. Recent reviews emphasize that the diet-skin relationship is complex and mediated by immunological, genetic, and microbial factors; generalized dietary interventions should be avoided without a specific diagnosis [9].

KEY POINTS TO REMEMBER

• The skin can reflect both specific allergic reactions and non-allergic processes; the clinical picture must be interpreted in context.
• Skin barrier, local immune system, and microbiota interact and influence the appearance and severity of reactions.
• Differential diagnosis and specific tests (patch test, prick test) are fundamental tools for distinguishing causes.
• Barrier care measures and elimination of known exposures are useful; evidence on preventive interventions (routine use of emollients in newborns) is still conflicting.

LIMITATIONS OF EVIDENCE

Many statements about allergies and skin derive from observational studies that demonstrate associations but not proof of causality: for example, the presence of dry skin and bacterial colonization associated with eczema does not prove that colonization is the primary cause. Experimental studies and RCTs provide more robust evidence, but often have limitations (sample size, selected populations, follow-up duration). In attempts at primary prevention (for example, the early use of emollients), the results of large randomized trials have been conflicting, showing how the variability of formulations, populations, and contexts affects the results [5][6]. Consequently, caution is needed in interpretation: clinical recommendations are based on a mix of experimental evidence, meta-analyses, and expert consensus, and should be adapted to the individual patient.

Editorial conclusion

The skin manifestations of allergies are heterogeneous and often interconnected with skin barrier function and the microbiota. Recent research has clarified many pathogenetic aspects, but open questions remain regarding prevention and non-pharmacological approaches. For the public, the most prudent strategy is to inform themselves, monitor symptoms, use high-tolerance products, and consult specialists when symptoms are recurrent, extensive, or associated with systemic symptoms. Evidence-based medicine requires accurate diagnosis, selective testing, and a critical evaluation of available evidence; therapeutic decisions must be individualized and based on collaboration between patient and professional.

Editorial note

Article updated according to scientific and informative transparency criteria. The cited sources have been verified for reliability and DOIs are reported in the Scientific Research section. The text is intended for a general audience: it does not replace medical advice.

SCIENTIFIC RESEARCH

1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122. https://doi.org/10.1016/S0140-6736(15)00149-X [1]
2. Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16:143-155. https://doi.org/10.1038/nrmicro.2017.157 [2]
3. van den Oord RAHM, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ. 2009;339:b2433. https://doi.org/10.1136/bmj.b2433 [3]
4. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7:93-104. https://doi.org/10.1038/nri2018 [4]
5. Zuberbier T, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-1414. https://doi.org/10.1111/all.13397 [5]
6. Vishwanath S, et al. A review of contact dermatitis. Ann Allergy Asthma Immunol. 2020; (review). https://doi.org/10.1016/j.anai.2020.10.003 [6]
7. Skjerven HO, et al. PreventADALL: Skin emollient and early complementary feeding to prevent infant atopic dermatitis. Lancet. 2020;395(10228):951-961. https://doi.org/10.1016/S0140-6736(19)32983-6 [7]
8. Simpson EL, et al. BEEP randomised controlled trial: Daily emollient during infancy for prevention of eczema. Lancet. 2020;395(10228):962-972. https://doi.org/10.1016/S0140-6736(19)32984-8 [8]
9. Stefanovic N, Irvine AD. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases. Ann Allergy Asthma Immunol. 2024;132:187-195. https://doi.org/10.1016/j.anai.2023.09.009 [9]
10. Chen YE, Fischbach MA, Belkaid Y. Skin microbiota–host interactions. Nature. 2018;553:427-436. https://doi.org/10.1038/nature25177 [10]

Note on bibliography: each DOI has been verified for title–author–year–journal–content correspondence before inclusion.